- $164.01m
- $141.55m
- $53.49m
- 44
- 22
- 81
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.8 | ||
| Price to Tang. Book | 13.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.79% | ||
| Return on Equity | -95.42% | ||
| Operating Margin | -19.94% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 26.38 | 34.46 | 35.36 | 42.16 | 53.49 | 68.15 | 88.15 | 11.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
Directors
- William Link NEC (75)
- Nicholas Curtis CEO (65)
- Thomas Staab CFO (53)
- Alan Connaughton COO (49)
- John McLaughlin DRC (69)
- Richard Lindstrom IND (73)
- Elizabeth O'Farrell IND (56)
- Aimee Weisner IND (52)
- Gary Winer IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 20th, 2004
- Public Since
- September 21st, 2020
- No. of Shareholders
- 80
- No. of Employees
- 140
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 11,790,440
- Address
- 2800 Discovery Drive, Suite 100, ORLANDO, 32826
- Web
- https://www.lensar.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for LNSR
Q1 2025 LENSAR Inc Earnings Release
Q2 2025 LENSAR Inc Earnings Release
Similar to LNSR
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the LENSAR share price?
As of Today at 21:44 UTC, shares in LENSAR are trading at $13.91. This share price information is delayed by 15 minutes.
How has the LENSAR share price performed this year?
Shares in LENSAR last closed at $13.91 and the price had moved by +305.54% over the past 365 days. In terms of relative price strength the LENSAR share price has outperformed the S&P500 Index by +274.33% over the past year.
What are the analyst and broker recommendations for LENSAR?
The overall consensus recommendation for LENSAR is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the LENSAR dividend yield?
LENSAR does not currently pay a dividend.
Does LENSAR pay a dividend?
LENSAR does not currently pay a dividend.
When does LENSAR next pay dividends?
LENSAR does not currently pay a dividend.
How do I buy LENSAR shares?
To buy shares in LENSAR you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of LENSAR?
As of the previous close price of $13.91, shares in LENSAR had a market capitalisation of $164.01m.
Where are LENSAR shares listed?
Here are the trading details for LENSAR:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LNSR
What kind of share is LENSAR?
Based on an overall assessment of its quality, value and momentum LENSAR is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a LENSAR share price forecast for 2025?
The analyst consensus target price for shares in LENSAR is $15.00. That is 7.84% above the last closing price of $13.91.
Analysts covering LENSAR currently have a consensus Earnings Per Share (EPS) forecast of -$0.39 for the next financial year.
Find out moreWhat is the trend in the LENSAR share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LENSAR. Over the past six months, its share price has outperformed the S&P500 Index by +176.62%.
As of the last closing price of $13.91, shares in LENSAR were trading +70.57% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the LENSAR PE Ratio?
The LENSAR PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $13.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of LENSAR?
LENSAR's management team is headed by:
- William Link - NEC
- Nicholas Curtis - CEO
- Thomas Staab - CFO
- Alan Connaughton - COO
- John McLaughlin - DRC
- Richard Lindstrom - IND
- Elizabeth O'Farrell - IND
- Aimee Weisner - IND
- Gary Winer - IND